# US 2004/0081983 A1 · Kinases and phosphatases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0081983 A1
- Document ID: US20040081983A1
- Status: Published application
- Kind: A1
- Application number: 10/466,759
- Filed: 2002-07-17
- Published: 2004-04-29
- Earliest claimed: 2002-07-17
- Inventors: Ernestine A. Lee; Narinder K. Chawla; Mariah R. Baughn; Craig H. Ison; Rajagopal Gururajan; Chandra S. Arvizu; Monique G. Yao; Jennifer L. Jackson; Y. Tom Tang; Henry Yue; Bao Tran; Li Ding; Dyung Aina Lu; Preeti G. Lal; Bridget A. Warren
- Web page: https://patentgrep.com/patent/US20040081983A1

## CPC

- C07H 21/04: with deoxyribosyl as saccharide radical
- C12N 9/12: transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N 9/16: acting on ester bonds (3.1)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides human kinases and phosphatases (KPP) and polynucleotides which identify and encode KPP. The invention also provides expression vector, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP.

## Claims

### Claim 1

An isolated polypeptide selected from the group consisting of:
a) a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8,
b) a polypeptide comprising a naturally occurring amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:1-8,
c) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, and
d) an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8.

### Claim 2 (depends on 1)

An isolated polypeptide of claim 1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8.

### Claim 3 (depends on 1)

An isolated polynucleotide encoding a polypeptide of claim 1.

### Claim 4 (depends on 2)

An isolated polynucleotide encoding a polypeptide of claim 2.

### Claim 5 (depends on 4)

An isolated polynucleotide of claim 4 comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:9-16.

### Claim 6 (depends on 3)

A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.

### Claim 7 (depends on 6)

A cell transformed with a recombinant polynucleotide of claim 6.

### Claim 8 (depends on 6)

A transgenic organism comprising a recombinant polynucleotide of claim 6.

### Claim 9 (depends on 1)

A method of producing a polypeptide of claim 1, the method comprising:
a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and
b) recovering the polypeptide so expressed.

### Claim 10 (depends on 9)

A method of claim 9, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1-8.

### Claim 11 (depends on 1)

An isolated antibody which specifically binds to a polypeptide of claim 1.

### Claim 12

An isolated polynucleotide selected from the group consisting of:
a) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:9-16,
b) a polynucleotide comprising a naturally occurring polynucleotide sequence at least 90% identical to a polynucleotide sequence selected from the group consisting of SEQ ID NO:9-16,
c) a polynucleotide complementary to a polynucleotide of a),
d) a polynucleotide complementary to a polynucleotide of b), and
e) an RNA equivalent of a)-d).

### Claim 13 (depends on 12)

An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 12.

### Claim 14 (depends on 12)

A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising:
a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and
b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

### Claim 15 (depends on 14)

A method of claim 14, wherein the probe comprises at least 60 contiguous nucleotides.

### Claim 16 (depends on 12)

A method of detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 12, the method comprising:
a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

### Claim 17 (depends on 1)

A composition comprising a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

### Claim 18 (depends on 17)

A composition of claim 17, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-8.

### Claim 19 (depends on 17)

A method for treating a disease or condition associated with decreased expression of functional KPP, comprising administering to a patient in need of such treatment the composition of claim 17.

### Claim 20 (depends on 1)

A method of screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:
a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
b) detecting agonist activity in the sample.

### Claim 21 (depends on 20)

A composition comprising an agonist compound identified by a method of claim 20 and a pharmaceutically acceptable excipient.

### Claim 22 (depends on 21)

A method for treating a disease or condition associated with decreased expression of functional KPP, comprising administering to a patient in need of such treatment a composition of claim 21.

### Claim 23 (depends on 1)

A method of screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:
a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
b) detecting antagonist activity in the sample.

### Claim 24 (depends on 23)

A composition comprising an antagonist compound identified by a method of claim 23 and a pharmaceutically acceptable excipient.

### Claim 25 (depends on 24)

A method for treating a disease or condition associated with overexpression of functional KPP, comprising administering to a patient in need of such treatment a composition of claim 24.

### Claim 26 (depends on 1)

A method of screening for a compound that specifically binds to the polypeptide of claim 1, the method comprising:
a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and
b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 1.

### Claim 27 (depends on 1)

A method of screening for a compound that modulates the activity of the polypeptide of claim 1, the method comprising:
a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,
b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and
c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.

### Claim 28 (depends on 5)

A method of screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method comprising:
a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,
b) detecting altered expression of the target polynucleotide, and
c) comparing the expression of the target polynucleotide in the presence of varying amounts of the compound and in the absence of the compound.

### Claim 29 (depends on 12)

A method of assessing toxicity of a test compound, the method comprising:
a) treating a biological sample containing nucleic acids with the test compound,
b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide of claim 12 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 12 or fragment thereof,
c) quantifying the amount of hybridization complex, and
d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

### Claim 30 (depends on 11)

A diagnostic test for a condition or disease associated with the expression of KPP in a biological sample, the method comprising:
a) combining the biological sample with an antibody of claim 11, under conditions suitable for the antibody to bind the polypeptide and form an antibody:polypeptide complex, and
b) detecting the complex, wherein the presence of the complex correlates with the presence of the polypeptide in the biological sample.

### Claim 31 (depends on 11)

The antibody of claim 11, wherein the antibody is:
a) a chimeric antibody,
b) a single chain antibody,
c) a Fab fragment,
d) a F(ab′)2 fragment, or
e) a humanized antibody.

### Claim 32 (depends on 11)

A composition comprising an antibody of claim 11 and an acceptable excipient.

### Claim 33 (depends on 32)

A method of diagnosing a condition or disease associated with the expression of KPP in a subject, comprising administering to said subject an effective amount of the composition of claim 32.

### Claim 34 (depends on 32)

A composition of claim 32, wherein the antibody is labeled.

### Claim 35 (depends on 34)

A method of diagnosing a condition or disease associated with the expression of KPP in a subject, comprising administering to said subject an effective amount of the composition of claim 34.

### Claim 36 (depends on 11)

A method of preparing a polyclonal antibody with the specificity of the antibody of claim 11, the method comprising:
a) immunizing an animal with a polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
b) isolating antibodies from said animal, and
c) screening the isolated antibodies with the polypeptide, thereby identifying a polyclonal antibody which binds specifically to a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8.

### Claim 37 (depends on 36)

A polyclonal antibody produced by a method of claim 36.

### Claim 38 (depends on 37)

A composition comprising the polyclonal antibody of claim 37 and a suitable carrier.

### Claim 39 (depends on 11)

A method of making a monoclonal antibody with the specificity of the antibody of claim 11, the method comprising:
a) immunizing an animal with a polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, or an immunogenic fragment thereof, under conditions to elicit an antibody response,
b) isolating antibody producing cells from the animal,
c) fusing the antibody producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells,
d) culturing the hybridoma cells, and
e) isolating from the culture monoclonal antibody which binds specifically to a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8.

### Claim 40 (depends on 39)

A monoclonal antibody produced by a method of claim 39.

### Claim 41 (depends on 40)

A composition comprising the monoclonal antibody of claim 40 and a suitable carrier.

### Claim 42 (depends on 11)

The antibody of claim 11, wherein the antibody is produced by screening a Fab expression library.

### Claim 43 (depends on 11)

The antibody of claim 11, wherein the antibody is produced by screening a recombinant immunoglobulin library.

### Claim 44 (depends on 11)

A method of detecting a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8 in a sample, the method comprising:
a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and
b) detecting specific binding, wherein specific binding indicates the presence of a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8 in the sample.

### Claim 45 (depends on 11)

A method of purifying a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8 from a sample, the method comprising:
a) incubating the antibody of claim 11 with a sample under conditions to allow specific binding of the antibody and the polypeptide, and
b) separating the antibody from the sample and obtaining the purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8.

### Claim 46 (depends on 13)

A microarray wherein at least one element of the microarray is a polynucleotide of claim 13.

### Claim 47 (depends on 46)

A method of generating an expression profile of a sample which contains polynucleotides, the method comprising:
a) labeling the polynucleotides of the sample,
b) contacting the elements of the microarray of claim 46 with the labeled polynucleotides of the sample under conditions suitable for the formation of a hybridization complex, and
c) quantifying the expression of the polynucleotides in the sample.

### Claim 48 (depends on 12)

An array comprising different nucleotide molecules affixed in distinct physical locations on a solid substrate, wherein at least one of said nucleotide molecules comprises a first oligonucleotide or polynucleotide sequence specifically hybridizable with at least 30 contiguous nucleotides of a target polynucleotide, and wherein said target polynucleotide is a polynucleotide of claim 12.

### Claim 49 (depends on 48)

An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 30 contiguous nucleotides of said target polynucleotide.

### Claim 50 (depends on 48)

An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to at least 60 contiguous nucleotides of said target polynucleotide.

### Claim 51 (depends on 48)

An array of claim 48, wherein said first oligonucleotide or polynucleotide sequence is completely complementary to said target polynucleotide.

### Claim 52 (depends on 48)

An array of claim 48, which is a microarray.

### Claim 53 (depends on 48)

An array of claim 48, further comprising said target polynucleotide hybridized to a nucleotide molecule comprising said first oligonucleotide or polynucleotide sequence.

### Claim 54 (depends on 48)

An array of claim 48, wherein a linker joins at least one of said nucleotide molecules to said solid substrate.

### Claim 55 (depends on 48)

An array of claim 48, wherein each distinct physical location on the substrate contains multiple nucleotide molecules, and the multiple nucleotide molecules at any single distinct physical location have the same sequence, and each distinct physical location on the substrate contains nucleotide molecules having a sequence which differs from the sequence of nucleotide molecules at another distinct physical location on the substrate.

### Claim 56 (depends on 1)

A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:1.

### Claim 57 (depends on 1)

A polypeptide of claim 1, comprising the amino acid sequence of SEQ TD NO:2.

### Claim 58 (depends on 1)

A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:3.

### Claim 59 (depends on 1)

A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:4.

### Claim 60 (depends on 1)

A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:5.

### Claim 61 (depends on 1)

A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:6.

### Claim 62 (depends on 1)

A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:7.

### Claim 63 (depends on 1)

A polypeptide of claim 1, comprising the amino acid sequence of SEQ ID NO:8.

### Claim 64 (depends on 12)

A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:9.

### Claim 65 (depends on 12)

A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:10.

### Claim 66 (depends on 12)

A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:11.

### Claim 67 (depends on 12)

A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:12.

### Claim 68 (depends on 12)

A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:13.

### Claim 69 (depends on 12)

A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:14.

### Claim 70 (depends on 12)

A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:15.

### Claim 71 (depends on 12)

A polynucleotide of claim 12, comprising the polynucleotide sequence of SEQ ID NO:16.
